You can buy or sell Vaxart and other stocks, options, ETFs, and crypto commission-free!
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. Read More The company was founded in 2004 and is headquartered in South San Francisco, CA.
South San Francisco, California
52 Week High
52 Week Low
Yahoo FinanceMay 9
Vaxart Announces First Quarter 2019 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- - $13 million raised in 1H19 - - Norovirus bivalent vaccine Phase 1b clinical study underway with results expected in 2H19 - Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the first quarter ended March 31, 2019. “With the Phase 1b study of our bivalent norovirus tablet vaccine underway and two successful financings behin...
Yahoo FinanceMay 7
Have Insiders Been Buying Vaxart, Inc. (NASDAQ:VXRT) Shares?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So shareholders might well want to know whether insiders have been buying or selling shares in Vaxart, Inc. (NASDAQ:VXRT). What Is Insider Buying? It's quite normal ...
Expected Aug 8, After Hours